# EDGAR Filing Document

**Accession Number:** 0001179929
**File Stem:** 0001437749-25-035490
**Filing Date:** 2025-11
**Character Count:** 11244
**Document Hash:** eacd4867f632a013fce4b47a828c44b3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-035490.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001437749-25-035490

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251117

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MOLINA HEALTHCARE, INC.
- **CENTRAL INDEX KEY:** 0001179929
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 134204626
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31719
- **FILM NUMBER:** 251492326

**BUSINESS ADDRESS:**
- **STREET 1:** 200 OCEANGATE, SUITE 100
- **CITY:** LONG BEACH
- **STATE:** CA
- **ZIP:** 90802
- **BUSINESS PHONE:** 5624353666

**MAIL ADDRESS:**
- **STREET 1:** 200 OCEANGATE, SUITE 100
- **CITY:** LONG BEACH
- **STATE:** CA
- **ZIP:** 90802

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MOLINA HEALTHCARE INC
- **DATE OF NAME CHANGE:** 20020812

?xml version='1.0' encoding='ASCII'? moh20251117_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 8-K**

------

**Current Report**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 17, 2025**

------

**MOLINA HEALTHCARE, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-31719** | **13-4204626** |
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

---

------

---

| | | | |
|:---|:---|:---|:---|
| **200 Oceangate, Suite 100,** | **Long Beach,** | **California** | **90802** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant**'**s telephone number, including area code: (562) 435-3666**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 Par Value  | MOH | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

---

| | |
|:---|:---|
| Emerging growth company  | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.

☐

------

**Item 7.01. Regulation FD Disclosure.**

On November 17, 2025, Molina Healthcare, Inc., a Delaware corporation (the "Company"), announced that it had priced $850 million aggregate principal amount of the Company's 6.500% senior notes due 2031 (the "Notes"), in a private offering to individuals reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to certain non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. The offering is expected to close on or about November 20, 2025, subject to the satisfaction of customary closing conditions. This Current Report on Form 8-K, including the information contained in Exhibit 99.1, does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other securities and shall not constitute an offer, solicitation or sale of any security in any jurisdiction in which such offering, solicitation or sale would be unlawful. The Notes have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction, and may not be offered or sold absent registration or an applicable exemption from the registration requirements of the Securities Act or the securities laws of any other jurisdiction.

On November 17, 2025, the Company issued a press release announcing the pricing of the Notes. A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K.

Note: The information in this Form 8-K and the exhibit attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits:

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 99.1 | [Press release of Molina Healthcare, Inc. issued November 17, 2025](ex_889778.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | MOLINA HEALTHCARE, INC. |
| Date: November 17, 2025 | By: | /s/ Jeff Barlow |
|  |  | Jeff Barlow<br> Chief Legal Officer and Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

![mh01.jpg](mh01.jpg)

**News Release**

**Investor Contact**: Jeff Geyer, <u>Jeffrey.Geyer@molinahealthcare.com</u>, 305-317-3012

**Media Contact**: Caroline Zubieta, <u>Caroline.Zubieta@molinahealthcare.com</u>, 562-951-1588

------

**Molina Healthcare Announces Pricing** <br> **of $850 Million of 6.500% Senior Notes Due 2031**

**Long Beach, Calif., November 17, 2025** – Molina Healthcare, Inc. (NYSE: MOH) (the "Company") today announced that it priced $850 million aggregate principal amount of its 6.500% senior notes due 2031 (the "Notes") to be sold in a private offering to individuals reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to certain non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. The offering is expected to close on or about November 20, 2025 (such actual closing date, the "Settlement Date"), subject to the satisfaction of customary closing conditions.

The Notes will not be guaranteed by any of the Company's subsidiaries at the time of issuance. The Notes will bear interest at a rate of 6.500% per year. Interest will be payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2026 and will accrue from the Settlement Date. The Notes will mature on February 15, 2031.

The Company estimates that after deducting fees and expenses payable by the Company, the net proceeds from the issuance and sale of the Notes will be approximately $838 million (the "Net Proceeds"). The Company intends to use the Net Proceeds for general corporate purposes, including to repay the Company's outstanding delayed draw term loans under its existing credit agreement.

The Notes have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, a U.S. person (as defined in Regulation S) except in transactions exempt from, or not subject to, the registration requirements of the Securities Act.

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the Notes and shall not constitute an offer, solicitation or sale in any state or jurisdiction where such offer, solicitation or sale is prohibited.

**About Molina Healthcare**

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit <u>molinahealthcare.com.</u>

------

MOH Announces Pricing of $850 Million of Senior Notes Due 2031

November 17, 2025

**Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995**

This press release contains forward-looking statements. The Company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this press release may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as "expects," "intends," "will," "may," or the negative of these terms or other similar expressions. Forward-looking statements contained in this press release include, but are not limited to, statements related to the Company's offering of the Notes and the intended use of the Net Proceeds of the offering, which are subject to risks and uncertainties, including, without limitation, risks related to whether the Company will consummate the offering of the Notes on the expected terms, or at all, market and other general economic conditions, and whether the Company will be able to satisfy the conditions required to close any sale of the Notes. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by its forward-looking statements will in fact occur, and it cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company's judgment as of the date hereof, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statements to conform the statement to actual results or changes in its expectations.

-END-